29 Aprile 2019

EMA recommends withdrawal of marketing authorisation for cancer medicine Olaratumab

April 26, 2019 – EMA has completed its assessment of the results of the ANNOUNCE study and concluded that Lartruvo (olaratumab) with doxorubicin does not prolong the lives of patients with soft tissue cancer more than doxorubicin alone. The Agency is therefore recommending that the marketing authorisation of the medicine be revoked. In January 2019, when preliminary results of the ANNOUNCE study became available, the Agency recommended that no new … (leggi tutto)